Business Description
Abeona Therapeutics Inc
NAICS : 325413
SIC : 2834
ISIN : US00289Y2063
Description
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.75 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 0.51 | |||||
| Debt-to-EBITDA | -0.36 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -60.7 | |||||
| 3-Year EBITDA Growth Rate | 51 | |||||
| 3-Year EPS without NRI Growth Rate | 47.3 | |||||
| 3-Year FCF Growth Rate | 43.7 | |||||
| 3-Year Book Growth Rate | -72.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 36.71 | |||||
| Future 3-5Y Total Revenue Growth Rate | 323.73 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.09 | |||||
| 9-Day RSI | 35.28 | |||||
| 14-Day RSI | 38.75 | |||||
| 6-1 Month Momentum % | 34.09 | |||||
| 12-1 Month Momentum % | 23.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.12 | |||||
| Quick Ratio | 6.12 | |||||
| Cash Ratio | 5.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -90.4 | |||||
| Shareholder Yield % | -40.41 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -1444.8 | |||||
| ROE % | -241.61 | |||||
| ROA % | -77.29 | |||||
| ROIC % | -440.62 | |||||
| ROC (Joel Greenblatt) % | -836.86 | |||||
| ROCE % | -86.8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 33.94 | |||||
| PB Ratio | 5.27 | |||||
| Price-to-Tangible-Book | 5.34 | |||||
| EV-to-EBIT | -2.37 | |||||
| EV-to-EBITDA | -2.48 | |||||
| EV-to-Revenue | 46 | |||||
| EV-to-Forward-Revenue | 10.72 | |||||
| EV-to-FCF | -3.18 | |||||
| Price-to-Net-Current-Asset-Value | 6.49 | |||||
| Price-to-Net-Cash | 7.05 | |||||
| Earnings Yield (Greenblatt) % | -42.12 | |||||
| FCF Yield % | -20.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abeona Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.5 | ||
| EPS (TTM) ($) | -2.69 | ||
| Beta | -2.06 | ||
| Volatility % | 71.23 | ||
| 14-Day RSI | 38.75 | ||
| 14-Day ATR ($) | 0.16713 | ||
| 20-Day SMA ($) | 6.00108 | ||
| 12-1 Month Momentum % | 23.33 | ||
| 52-Week Range ($) | 3.12 - 8.8 | ||
| Shares Outstanding (Mil) | 43.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abeona Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abeona Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abeona Therapeutics Inc Frequently Asked Questions
What is Abeona Therapeutics Inc(LTS:0H7R)'s stock price today?
The current price of LTS:0H7R is $5.71. The 52 week high of LTS:0H7R is $8.80 and 52 week low is $3.12.
When is next earnings date of Abeona Therapeutics Inc(LTS:0H7R)?
The next earnings date of Abeona Therapeutics Inc(LTS:0H7R) is 2025-03-18 Est..
Does Abeona Therapeutics Inc(LTS:0H7R) pay dividends? If so, how much?
Abeona Therapeutics Inc(LTS:0H7R) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers